Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dordaviprone Hydrochloride

Phase 1Small molecule

NNational Cancer Institute (NCI)

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

ColorectalRecruiting

ColorectalPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Colorectal

NCT05630794

Clinical

Trials by Indication[1]

Colorectal1 trial

Phase I Trial of ONC201 for Chemoprevention of Colorectal Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05630794·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dordaviprone Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dordaviprone Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dordaviprone Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

Related News